Posters

      Ionic Liquid GCxGC-TOF-MS Approach For Generic Screening Of Aerosol Constituents In Aqueous Tobacco Aerosol Fractions And Analysis Of Microsomal Incubates

      Dutertre, Q.; Knorr, A.; Debrick , A.; Almstetter, M.; Martin, E.; Bentley, M.
      Conference date
      Sep 29, 2013
      Conference name

      ISSX 2013
      Link to more information
      Topic
      Summary

      The lung is the predominant target organ for chemically induced damage by tobacco aerosol constituents. While metabolism by oxidative enzymes and subsequent conjugation with endogenous compounds generally results in their detoxification and excretion from the body, it can also lead to the production of more toxic metabolites. In vitro metabolic investigations using microsomes, a well-established test system, were used to investigate the potential toxification of tobacco aerosol related xenobiotics. In addition, parent compound kinetics were also investigated using comprehensive two-dimensional gas chromatography coupled to fast acquisition time-of-flight mass spectrometry (GCxGC-TOF-MS). GCxGC-TOF-MS is a widely established method for non-targeted analyses, suitable for the analysis of highly complex matrices such as tobacco aerosols. Aqueous trapping solutions perfused with tobacco aerosol as well as microsomal incubate were injected directly on-column and analyzed by GCxGC-TOF-MS using a combination of water resistant ionic liquid based analytical columns. In the absence of a solvent front, this setup enables the detection of highly volatile constituents, including furans. This method represents a novel approach, which defies the common belief that aqueous media are incompatible with gas chromatography. Furan compounds are naturally present in tobacco leaves and are further generated during the smoking of tobacco products by thermal degradation. Furan and alkylfurans are rapidly metabolized by microsomes as a substrate of cytochrome P450 2E1-catalyzed oxidation, which leads to the generation of reactive intermediates (like cis-1,4-butendial by furan oxidative CYP activation), whereas furfural and furfuryl alcohol are predominantly detoxified. A mixture of furan, alkylfurans, furfural, furfuryl alcohol and 5-methylfurfuryl alcohol was investigated for phase i metabolism using human liver and lung microsomes. The kinetics for parent compound transformation rates were determined by GCxGC-TOF-MS measurements in parallel with a LC high resolution MS approach for gaining complementary information regarding any reactive metabolites. In addition to that, we analysed reactive intermediate metabolites using nucleophile trapping. Potentially unknown furan metabolites were investigated using non-targeted data analysis complemented by in silico metabolism prediction using meteor Nexus®. The impact of microsomal activation upon aqueous tobacco aerosol fractions was also investigated using a non-targeted workflow for parent compound kinetics. 

      Related Publications

      Selected Aldehydes Yields in the Aerosol of Commercial Electronic Cigarettes

      Aerosol Chemistry

      Quantitation of Selected Elements in the Aerosol of Electrically Heated Tobacco Products (eHTPs) by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

      Aerosol Chemistry

      Heating vs. Burning: A Non-Targeted Analytical Characterization of Compounds with Higher Abundance in the Aerosol of a Heated Tobacco Product than in Mainstream Cigarette Smoke

      Aerosol Chemistry

      Statistical Derivation of a Fold-Change Cut-Off for Non-Targeted Differential Screening Studies Based on Analytical Method Variability

      Aerosol Chemistry

      Pitfalls in the Detection of Volatiles Associated with Heated Tobacco and e-Vapor Products When Using PTR-TOF-MS

      Aerosol Chemistry

      Non-targeted analytical comparison of a heated tobacco product aerosol against mainstream cigarette smoke: does heating tobacco produce an inherently different set of aerosol constituents?

      Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.